Wedbush raised the firm’s price target on Stoke Therapeutics (STOK) to $38 from $36 and keeps an Outperform rating on the shares. The firm notes the company released their 10-K filing and while no separate press release was issued, all key objectives remain on track for the company. Most important in the near term remains the enrollment completion for the Phase 3 EMPEROR study of zorevunersen in Dravet Syndrome.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- STOK Earnings this Week: How Will it Perform?
- Stoke Therapeutics, Biogen publish data from zorevunersen studies in NEJM
- Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP
- Stoke Therapeutics Awards Discretionary Bonus to CEO Smith
- Stoke Therapeutics initiated with an Outperform at Wolfe Research